Form 4: Altimmune CEO Buys 15,000 Shares in Planned Transaction

Altimmune, Inc.'s President and CEO, Jerome Benedict Durso, acquired 15,000 shares of common stock at $3.14 per share through a pre-arranged plan.

Summary

• Jerome Benedict Durso, who serves as President and CEO, Director, and a 10% owner of Altimmune, Inc., purchased 15,000 shares of the company's common stock.
• The transaction is reported to have occurred on April 1, 2026, with shares acquired at a price of $3.14 each.
• Following this acquisition, Durso's total beneficial ownership in Altimmune common stock will be 47,500 shares.
• This purchase was executed under a Rule 10b5-1(c) pre-arranged trading plan, indicating a scheduled transaction.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a CEO's purchase of shares, even if pre-planned, indicates confidence in the company's valuation and future prospects.

Positives

• An insider, specifically the President and CEO, purchased shares, which typically signals confidence in the company's future prospects and valuation.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, suggesting a pre-meditated investment strategy rather than a reaction to immediate market fluctuations.

Future Outlook

This filing reports a specific insider transaction and does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that insider purchases, particularly by a company's President and CEO, are generally interpreted by the market as a strong vote of confidence in the company's current valuation and future prospects. In the biotechnology sector, where companies often face significant development risks and long timelines, such insider buying can be a particularly reassuring signal to investors.

Comparison to Industry Standards

• Insider buying activity is a widely observed indicator across all industries. While the 15,000 shares acquired by Altimmune's CEO is not a massive institutional purchase, it represents a direct personal investment.
• For a biotechnology company like Altimmune, insider confidence can be a more critical factor compared to more mature, stable industries, especially when contrasted with peers where management might be divesting shares.
• No specific comparable companies, projects, or numerical results are provided within the filing to allow for a direct quantitative comparison to industry benchmarks.

Related Party Transactions

• The reported transaction itself is a related party dealing, involving the purchase of company stock by a key executive and director.

Stakeholder Impact

• Shareholders: May perceive the CEO's share purchase as a positive indicator of management's belief in the company's value, potentially fostering increased investor confidence.
• Employees: Could interpret the CEO's investment as a sign of stability and strong belief in the company's long-term success.

Key Dates

Recommendation

The CEO's decision to purchase shares, even under a Rule 10b5-1 plan, is a positive signal of management's confidence in Altimmune's future and current valuation. This action suggests potential upside or undervaluation. However, a single insider transaction, without accompanying operational or financial updates, primarily reinforces a 'hold' position for existing investors and warrants further comprehensive due diligence for potential new investors rather than a strong buy recommendation.

Keywords

Altimmune, ALT, Insider Trading, Form 4, Stock Purchase, CEO, Jerome Durso, Rule 10b5-1, Biotechnology